Drugs / DAVANAT
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00054977 | Feb 2003 → Apr 2005 | breast cancer, colorectal cancer, head and neck cancer, lung cancer +1 | Galectin Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01723813 | Apr 2012 → Apr 2015 | metastatic melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00388700 | Oct 2006 → Jun 2009 | colorectal cancer | Galectin Therapeutics Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00386516 | Sep 2006 → Jun 2009 | bile duct cancer, gallbladder cancer | Galectin Therapeutics Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00110721 | May 2005 → Jun 2007 | colorectal cancer | Galectin Therapeutics Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DAVANAT | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297960 ↗ |
| Known as | Galactomannan c | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297960 ↗ |
| Known as | GM-CT-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00054977 ↗ |
| Action | Inhibit | “capacity to inhibit galectins” NCT01723813 ↗ |
| Modality | Other / unclassified | “the large carbohydrate molecule GM-CT-01” NCT00386516 ↗ |
| Route | Intravenous | “IV infusion over 30 minutes” NCT00054977 ↗ |
| Target | LGALS1 | “Galectin-1 inhibitor” CHEMBL4297960 ↗ |
| Target | LGALS3 | “Galectin-3 inhibitor” CHEMBL4297960 ↗ |